0001562180-22-003409.txt : 20220414 0001562180-22-003409.hdr.sgml : 20220414 20220414204547 ACCESSION NUMBER: 0001562180-22-003409 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220412 FILED AS OF DATE: 20220414 DATE AS OF CHANGE: 20220414 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Horstmeier Paul CENTRAL INDEX KEY: 0001780978 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38993 FILM NUMBER: 22828779 MAIL ADDRESS: STREET 1: C/O HEALTH CATALYST, INC. STREET 2: 3165 E. MILLROCK DRIVE #400 CITY: SALT LAKE CITY STATE: UT ZIP: 84121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Health Catalyst, Inc. CENTRAL INDEX KEY: 0001636422 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370] IRS NUMBER: 453337483 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10897 SOUTH RIVER FRONT PARKWAY, #300 CITY: SOUTH JORDAN STATE: UT ZIP: 84095 BUSINESS PHONE: 801-708-6800 MAIL ADDRESS: STREET 1: 10897 SOUTH RIVER FRONT PARKWAY, #300 CITY: SOUTH JORDAN STATE: UT ZIP: 84095 FORMER COMPANY: FORMER CONFORMED NAME: HQC Holdings, Inc. DATE OF NAME CHANGE: 20150312 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2022-04-12 false 0001636422 Health Catalyst, Inc. HCAT 0001780978 Horstmeier Paul C/O HEALTH CATALYST, INC. 10897 SOUTH RIVER FRONT PARKWAY, #300 SOUTH JORDAN UT 84095 false true false false Chief Operating Officer Common Stock 2022-04-12 4 M false 520.00 15.84 A 180836.00 D Common Stock 2022-04-12 4 M false 4167.00 15.84 A 185003.00 D Common Stock 2022-04-12 4 M false 521.00 10.80 A 185524.00 D Common Stock 2022-04-12 4 S false 5208.00 25.1623 D 180316.00 D Stock Option (Right to Buy) 15.84 2022-04-12 4 M false 4167.00 0.00 D 2029-02-05 Common Stock 4167.00 35402.00 D Stock Option (Right to Buy) 15.84 2022-04-12 4 M false 520.00 0.00 D 2029-02-05 Common Stock 520.00 5728.00 D Stock Option (Right to Buy) 10.80 2022-04-12 4 M false 521.00 0.00 D 2028-09-27 Common Stock 521.00 18474.00 D The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person in accordance with Rule 10b5-1. 25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023. 25% of the 25,000 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023. 25% of the 18,995 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022. /s/ Jason Alger, as Attorney-in-Fact 2022-04-14